antidepressants, antipsychotics, analgesics and antitussives, beta adrenergic blocking agents, antiarrythmics and antiemetics. The gene is highly polymorphic in the human population; certain alleles result in the poor metabolizer phenotype, characterized by a decreased ability to metabolize the enzyme's ...
CYP2D6 metabolizes more than 25% of current commonly used drugs including antidepressants, antipsychotics, analgesics, beta-adrenergic blocking agents, antiarrythmics, and antiemetics. The CYP2D6 gene is highly polymorphic in humans, resulting in phenotypes that vary from poor metabolizer to super ...
Results Our preliminary data (N=40) showed a trend of association with CYP2D6 metabolizer status. Individuals that were either poor or intermediate metabolizers of this liver enzyme were more likely to have experienced AIM when given serotonergic antidepressants (x2=3.14, p=0.077). Discussion Our...
另外,还发现了编码不同亚型的剪接转录变体。 This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes ...
In blacks, the frequency of poor metabolizers is greater than for whites (1.6% vs. 0.44%)[3]. The occurrence of CYP2D6 ultrarapid metabolisers appears to be greater amongst Middle Eastern and North African populations[4]. This variability is accounted for by the differences in the ...
CYP2D6 metabolizes more than 25% of current commonly used drugs including antidepressants, antipsychotics, analgesics, beta-adrenergic blocking agents, antiarrythmics, and antiemetics. The CYP2D6 gene is highly polymorphic in humans, resulting in phenotypes that vary from poor metabolizer to super ...
antidepressantsamongpoor,intermediate,extensiveandultrarapidmetabolizers.(药物动力学参数）•Results:14个抗抑郁药,对于代谢类型为 extensive,intermediateandpoor metabolizersofeitherCYP2D6orCYP2C19给予不同的剂量.对于三环类抗抑郁药物,或者是CYP2D6的底物或者CYP2C19的底物的不良代谢者，他的使用量降低了，而选择性5羟...
antidepressants, antipsychotics, analgesics and antitussives, beta adrenergic blocking agents, antiarrythmics and antiemetics. The gene is highly polymorphic in the human population; certain alleles result in the poor metabolizer phenotype, characterized by a decreased ability to metabolize the enzymes ...
Thus, a poor metabolizer that is inaccurately classified as a normal metabolizer may reach supratherapeutic levels of an antidepressant at standard dosing and be at greater risk of side effects, whereas an ultrarapid metabolizer classified as a normal metabolizer may not reach therapeutic levels if ...
Poor metabolizers (PMs) display two inac- tive alleles and are characterized by deficient hydroxyl- ation of several classes of drugs, such as -blockers, antiarrhythmics, antidepressants, neuroleptics and some opioid analgesics. In approximately 7–10% of the Cauca- sian populations, an ...